TK-6302

About T-Knife Therapeutics

T-Knife Therapeutics is a private, pre-clinical stage biotech company pioneering next-generation TCR-T cell therapies for solid tumors. Its core differentiation lies in the proprietary MyT™ platform, which generates fully human, high-affinity TCRs, combined with internally developed enhancements like novel CD8 coreceptors and switch receptors. The company's lead candidate, TK-6302, targeting the PRAME antigen, is planned to enter Phase 1 trials in 2026, positioning T-Knife in the competitive but high-potential field of engineered cell therapies for oncology. With seasoned leadership and strong academic roots from the Max Delbrück Center and Charité in Berlin, T-Knife is advancing a pipeline aimed at addressing high unmet medical needs.

Therapeutic Areas

Other PRAME-positive solid tumors Drugs